The new anticoagulant requires less monitoring, and research indicates a lower stroke or bleeding risk. ... the University of California San Francisco and chief of anticoagulation and thrombosis services at the San Francisco VA Medical Center.
This month's column features questions from readers.
The primary outcome was device-pocket hematoma that necessitated prolonged hospitalization, interruption of anticoagulation, or further surgery. ... causes the bleeding to appear only postoperatively when full-dose anticoagulation is resumed.
methods of stroke prevention, adjusted-dose oral vitamin K antagonist (VKA) therapy, and management of bleeding on oral anticoagulation, among other topics. ... When oral anticoagulation is recommended or suggested, the guidelines suggest using a novel
This month's issue discusses implantation of endovascular therapy in stroke, reversal agents for the direct oral anticoagulants, antibiotics at the end of life, and more. ... In our story, anticoagulation experts explain that although the drug is
Direct oral anticoagulants (DOACs) and warfarin carried similar risks of death and major bleeding in the first 90 days of venous thromboembolism (VTE) treatment, a recent multicenter study found. ... as a treatment option for patients with venous
2010; 152:101-13. ). Patients who need long-term anticoagulation should be restarted on anticoagulant therapy in a timely manner. ... Kuchipudi A, Cheema G, et al.Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial
Anticoagulation with heparin, warfarin, or thrombolytic agents is believed to help incite this condition. ... Although this patient likely has underlying vascular disease, he has not had an invasive procedure or anticoagulation and lacks any of the
The non-vitamin K oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban are recommended over warfarin in eligible patients with atrial fibrillation, according to one of several recommendations in an updated ... 2. DS. 2. -VASc score
The American Heart Association's scientific statement offers recommendations on monitoring and reversal of non-vitamin K antagonist oral anticoagulants (NOACs), among other topics. ... Similarly, the statement said, risks of recurrent thromboembolic